Editorial Staff

Transparency, Please! MBTA Resists Disclosure of Arbitration Award

/in , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Joe Selvaggi talks with attorney for Pioneer Public Interest Law Center (PPILC) John La Liberte, about the work he did to successfully gain access to the MBTA retirement fund’s arbitration agreement after a seven-month legal struggle.

Follow on Apple Follow on Spotify Follow on Stitcher

Guest:

John La Liberte has been a litigator at a prestigious Boston boutique firm for over 30 years where he has also served as the firm’s general counsel. John
decided that he wanted to join Pioneer Public Interest Law Center to do what he hoped to do when he went to law school — engage in impact litigation.
WATCH:

Recent Episodes

The Oldest Hatred: Calling Out Antisemitism In Its Many Forms

Hubwonk host Joe Selvaggi talks with Boston Globe opinion writer Jeff Jacoby about the troubling increase in antisemitic incidents, including the recent attack on a Boston rabbi, and how our current political rancor fans the flames of bigotry nationwide.

Court Preserves Privacy: First Amendment Ruling Defends Non-Profits From Modern-Day McCarthyism

Hubwonk Host Joe Selvaggi talks with CATO research fellow and constitutional scholar Trevor Burrus about the recent Supreme Court ruling, Americans For Prosperity Foundation v. Bonta, reaffirming the right to privacy by denying the state of California the right to compel non-profits to disclose their list of donors.

Renters’ Unsung Heroes: Small Landlords Endure Without Income or Relief

Hubwonk host Joe Selvaggi talks with MassLandlords’ Doug Quattrochi about ways landlords faced the challenges of being caught between tenants unable to pay rent during COVID-19 shutdown and having little or no programmatic relief from state and federal agencies.

Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

Hubwonk host Joe Selvaggi talks with precision medicine expert Hannah Mamuszka and Pioneer Institute's Bill Smith about the promises and pitfalls of the newly approved Alzheimer’s drug Aduhelm, and the challenges presented when new, expensive drugs of dubious benefit are introduced to the nation’s formulary.